tiprankstipranks
Advertisement
Advertisement
Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor
PremiumTipRanks NewswireNuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor
25d ago
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush
Premium
TipRanks Newswire
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush
1M ago
Jade Biosciences Secures Exclusive Antibody License Agreement
Premium
Company Announcements
Jade Biosciences Secures Exclusive Antibody License Agreement
2M ago
Jade Biosciences Launches Major Underwritten Equity Offering
PremiumCompany AnnouncementsJade Biosciences Launches Major Underwritten Equity Offering
2M ago
JADE101 Phase 1 Trial Marks Key Early Milestone for Jade Biosciences Investors
Premium
Company Announcements
JADE101 Phase 1 Trial Marks Key Early Milestone for Jade Biosciences Investors
2M ago
Jade Biosciences 10M share Secondary priced at $15.00
Premium
The Fly
Jade Biosciences 10M share Secondary priced at $15.00
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100